STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

GEO Buys 2.24M XFOR Shares via Private Placement; Registration Rights Included

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. received a Schedule 13D/A disclosing that Growth Equity Opportunities 18 VGE, LLC (GEO) and affiliated NEA entities participated in a private placement that closed on August 13, 2025. GEO purchased 1,734,184 shares of Common Stock at $1.42 per share and pre-funded warrants to acquire 5,311,810 shares at $1.419 each with a $0.001 exercise price, financed from GEO's working capital.

After the transaction GEO directly owns 2,233,744 shares and, taking into account exercisable pre-funded warrants and ownership limitations, has a total deemed ownership of 2,243,658 shares, representing 9.99% of the outstanding common stock based on 22,459,047 shares. The filing states the acquisition was for investment purposes and includes registration rights and related agreements filed by the issuer.

Positive

  • Material minority stake disclosed: GEO's total deemed ownership of 2,243,658 shares equals 9.99% of outstanding common stock, providing transparency to investors.
  • Private placement closed: GEO purchased shares and pre-funded warrants using working capital at specified prices ($1.42 per share; $1.419 per pre-funded warrant), showing committed institutional funding.
  • Registration rights secured: A Registration Rights Agreement was entered, which facilitates future resale/liquidity for the registrable securities.

Negative

  • None.

Insights

TL;DR: NEA-affiliated GEO acquired a near-10% stake via a private placement, increasing strategic exposure while staying below typical control thresholds.

The transaction adds 2.24 million shares to GEO's position and uses pre-funded warrants to permit near-term additional ownership without immediate dilution to public float. The purchase price of $1.42 per share and $1.419 per pre-funded warrant signals the private placement valuation paid by institutional investors. Registration rights were obtained, which facilitates future liquidity for the registrable securities. The filing explicitly states investment intent and disclaims plans to seek board or corporate changes.

TL;DR: The investors took steps to preserve liquidity and registration rights while limiting immediate control implications.

The use of pre-funded warrants with a nominal exercise price and an ownership cap (initially 4.99% adjustable up to 19.99% with notice) is a governance mechanism that balances investor flexibility with limits on automatic control aggregation. The filing confirms there are no present plans to pursue extraordinary transactions or board changes, and includes a registration rights agreement governing resale mechanics. All disclosures appear routine and consistent with a minority institutional investment.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Growth Equity Opportunities 18 VGE, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
NEA 18 Venture Growth Equity, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
NEA Partners 18 VGE, L.P.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
NEA 18 VGE GP, LLC
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:08/15/2025
Ali Behbahani
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Ali Behbahani
Date:08/15/2025
Carmen Chang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Carmen Chang
Date:08/15/2025
Anthony A. Florence, Jr.
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
Date:08/15/2025
Mohamad H. Makhzoumi
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:08/15/2025
Edward T. Mathers
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Edward T. Mathers
Date:08/15/2025
Scott D. Sandell
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
Date:08/15/2025
Paul Walker
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Paul Walker
Date:08/15/2025
Rick Yang
Signature:/s/ Zachary Bambach
Name/Title:Zachary Bambach as attorney-in-fact for Rick Yang
Date:08/15/2025
Comments accompanying signature:
This Amendment No. 3 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.

FAQ

How many XFOR shares does GEO beneficially own after the transaction?

GEO directly owns 2,233,744 shares and has a deemed total ownership of 2,243,658 shares (9.99% of the class).

What did GEO pay per share and per pre-funded warrant in the private placement?

GEO paid $1.42 per share for common stock and $1.419 per pre-funded warrant, with the pre-funded warrant exercise price at $0.001 per share.

When did the private placement close and how many securities were issued overall?

The Private Placement closed on August 13, 2025, with the issuer issuing an aggregate of 11,040,776 shares of common stock and 31,234,731 pre-funded warrants to investors.

What is GEO's stated purpose for acquiring the shares?

The filing states GEO acquired the shares for investment purposes and disclaims any present plans to effect changes to management, board composition, capitalization, or corporate structure.

Are there limits on exercising the pre-funded warrants acquired by GEO?

Yes, the 2025 GEO Pre-Funded Warrants include an exercise limitation that prevents GEO from beneficially owning in excess of 4.99% unless GEO gives 61 days' prior notice to increase that limit, not to exceed 19.99%.
X4 Pharmaceuticals Inc

NASDAQ:XFOR

XFOR Rankings

XFOR Latest News

XFOR Latest SEC Filings

XFOR Stock Data

332.26M
80.32M
8.07%
83.45%
6.93%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON